Atezolizumab, Gemcitabine Hydrochloride, and Cisplatin as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer

Status: Active

Description

This randomized phase II trial studies how well atezolizumab works when given together with gemcitabine hydrochloride and cisplatin as first-line therapy in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes, or other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with chemotherapy may kill more tumor cells.

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed urothelial carcinoma of the bladder, ureter, urethra, or renal pelvis by the enrolling institution; patients with mixed histologies are required to have a predominant urothelial component as reviewed by the pathologist at the enrolling institution
  • Locally advanced (T4b, any N; any T, N2-3) or metastatic (M1) disease as determined by the treating investigator
  • Life expectancy >= 12 weeks
  • The patient must have measurable disease according to RECIST v1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the below pathology criteria; subject must agree to undergo two research-directed biopsies during treatment
  • Patients must have adequate tumor tissue available for PD-L1 testing; adequate tumor tissue is defined as: * For core-needle biopsy specimens, at least three cores should be submitted for evaluation if feasible; acceptable samples include core-needle biopsies for deep tumor tissue (minimum of three cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions; samples collected from fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases without a soft tissue component, and lavage are not acceptable * For pre-treatment archival tissue, representative urothelial carcinoma formalin-fixed paraffin-embedded (FFPE) tumor specimens (tumor blocks or 30 unstained slides) must be provided; patients with < 30 slides may be enrolled after discussion with the MSK principal investigator * Primary or metastatic specimens (with the exception of bone because it is not evaluable for PD-L1 expression) may be submitted
  • Absolute neutrophil count >= 1500 cells/uL (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • White blood cell (WBC) counts > 2500/uL (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • Lymphocyte count >= 300/uL (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • Platelet count >= 100,000/uL (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • Hemoglobin >= 9.0 g/dL (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained within 14 days prior to the first study treatment [cycle 1, day 1]) with the following exception: * Patients with known Gilbert disease who have total bilirubin level =< 3 x ULN may be enrolled
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (obtained within 14 days prior to the first study treatment [cycle 1, day 1]) with the following exception: * Patients with liver metastases may enroll with AST and ALT =< 5 x ULN
  • Alkaline phosphatase =< 2.5 x ULN (obtained within 14 days prior to the first study treatment [cycle 1, day 1]) with the following exception: * Patients with documented liver or bone metastases may enroll with alkaline phosphatase =< 5 x ULN
  • Estimated glomerular filtration rate (eGFR) >= 50 ml/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (obtained within 14 days prior to the first study treatment [cycle 1, day 1])
  • For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 5 months after the last dose of atezolizumab
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN * This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose
  • Ability and willingness to comply with the requirements of the study protocol

Exclusion Criteria

  • Prior chemotherapy or immunotherapy for metastatic urothelial cancer; prior neoadjuvant or adjuvant chemotherapy with first progression > 12 months is allowed; prior intravesical treatments such as Bacillus Calmette-Guerin (BCG) are allowed, however no BCG is allowed within 4 weeks prior to initiation of study treatment
  • Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment; however, the following are allowed: * Hormone-replacement therapy or oral contraceptives * Herbal therapy > 1 week prior to cycle 1, day 1; herbal therapy intended as anticancer therapy must also be discontinued at least 1 week prior to cycle 1, day 1 * Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1
  • Bisphosphonate therapy for symptomatic hypercalcemia * Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
  • Patients with a history of or active bone marrow disorders expected to interfere with study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma)
  • Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: ** Evaluable or measurable disease outside the CNS ** No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) ** No history of intracranial hemorrhage or spinal cord hemorrhage ** No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted ** No neurosurgical resection or brain biopsy within 28 days prior to cycle 1, day 1 * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: ** Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study ** No stereotactic radiation or whole-brain radiation within 28 days prior to cycle 1, day 1 * Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids
  • Pregnancy, lactation, or breastfeeding
  • Evidence of New York Heart Association (NYHA) functional class III or IV heart disease
  • Sensory or motor peripheral neuropathy >= grade 2
  • Hearing loss >= grade 2
  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
  • History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis * Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible * Patients with celiac disease controlled on diet alone * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: ** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations ** Rash must cover less than 10% of body surface area (BSA) ** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) ** No acute exacerbations of underlying condition within the last 12 months (i.e. not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan * History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
  • History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • Active tuberculosis
  • Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
  • Received oral or IV antibiotics within 2 weeks prior to cycle 1, day 1 * Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
  • Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study * Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
  • Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as but not limited to adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)
  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents * Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: ** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose ** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade 3 and 4)
  • Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1
  • Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half-lives of the investigational product, whichever is longer)
  • Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 * Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

Locations & Contacts

Illinois

Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Contact: Peter H. O'Donnell
Phone: 773-702-7564

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770
Montvale
Memorial Sloan Kettering Bergen
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770

New York

Commack
Memorial Sloan Kettering Commack
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770
Uniondale
Memorial Sloan Kettering Nassau
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770
West Harrison
Memorial Sloan Kettering Westchester
Status: Active
Contact: Samuel A. Funt
Phone: 646-888-4770

Ohio

Columbus
Ohio State University Comprehensive Cancer Center
Status: Active
Contact: Amir Mortazavi
Phone: 614-293-2886

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of atezolizumab combined with gemcitabine hydrochloride (gemcitabine) and cisplatin chemotherapy (GC) in different dosing schedules in patients with metastatic urothelial carcinoma (mUC), as measured by best confirmed overall response rate (ORR) (partial and complete responses) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

SECONDARY OBJECTIVES:

I. To determine safety and assess other parameters of clinical efficacy.

EXPLORATORY OBJECTIVES:

I. To determine the effects of atezolizumab alone (schedule 3, biopsy 1) and GC alone (schedule 2, biopsy 1) on CD8+ T-cells, immunosuppressive cell types, IFNgamma gene signatures, and immune checkpoint proteins.

II. To determine how the addition of GC to atezolizumab in schedule 1 alters CD8+ T-cell infiltration, immunosuppressive cell types, IFNgamma gene signatures, and immune checkpoint proteins.

III. To determine how the addition of atezolizumab to GC in schedule 2 alters CD8+ T-cell infiltration, immunosuppressive cell types, IFNgamma gene signatures, and immune checkpoint proteins.

IV. To determine if GC primes tumors for immune response by increasing the somatic mutation load (2nd biopsy in schedule 3 and both biopsies in schedule 2).

V. To determine how atezolizumab and GC alter the T cell receptor (TCR) repertoire in the peripheral blood.

OUTLINE: Patients are randomized to 1 of 3 schedules.

SCHEDULE I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1. Beginning in cycle 3, patients also receive gemcitabine hydrochloride IV on days 1 and 8, and cisplatin IV on day 1 or days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients that have to discontinue cisplatin-gemcitabine therapy for reasons of toxicity are permitted to commence treatment with carboplatin-gemcitabine chemotherapy at the discretion of the investigator in consultation with the Memorial Sloan-Kettering (MSK) principal investigator or MSK co-principal investigator. Carboplatin should be given IV drip per local institutional guidelines. Beginning after cycle 8, patients may receive atezolizumab IV over 30-60 minutes every 21 days for up to 18 doses in the absence of disease progression or unacceptable toxicity.

SCHEDULE II: Patients receive gemcitabine hydrochloride IV on days 1 and 8, and cisplatin IV on day 1 or days 1 and 8. Beginning in cycle 3, patients also receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients that have to discontinue cisplatin-gemcitabine therapy for reasons of toxicity are permitted to commence treatment with carboplatin-gemcitabine chemotherapy at the discretion of the investigator in consultation with the MSK principal investigator or MSK co-principal investigator. Beginning after cycle 6, patients may receive atezolizumab IV over 30-60 minutes every 21 days for up to 20 doses in the absence of disease progression or unacceptable toxicity.

SCHEDULE III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Beginning cycle 2, patients receive gemcitabine hydrochloride IV on days 1 and 8, cisplatin IV on day 1 or days 1 and 8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Patients that have to discontinue cisplatin-gemcitabine therapy for reasons of toxicity are permitted to commence treatment with carboplatin-gemcitabine chemotherapy at the discretion of the investigator in consultation with the MSK principal investigator or MSK co-principal investigator. Carboplatin should be given IV drip per local institutional guidelines. Beginning after cycle 7, patients receive atezolizumab over 30-60 minutes every 21 days for up to 19 doses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 9 weeks for up to 1.5 years and then every 12 weeks.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Samuel A. Funt

Trial IDs

Primary ID 16-1621
Secondary IDs NCI-2017-00748
Clinicaltrials.gov ID NCT03093922